Aquestive Therapeutics, Inc. (AQST), Monday announced that the U.S. Food and Drug Administration has accepted the company's New Drug Application for Anaphylm for the treatment of Type 1 allergic reactions.
Also, the agency has assigned a Prescription Drug User Fee Act target action date of January 31, 2026.
The company further stated that the FDA might decide to conduct an Advisory Committee meeting for the approval of Anaphylm.
If approved, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.
In the pre-market hours, AQST is trading at $3.69, up 7.89 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.